Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
RNA compared with SENS: revenue, margins and what each company keeps, and the suppliers and customers both name
RNA
Atrium Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
SENS
Senseonics Holdings, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
RNA
Atrium Therapeutics, Inc.
vs
SENS
Senseonics Holdings, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
RNA, solid
SENS, dashed
Supply-chain overlap
Revenue flow
RNA: latest quarter is a loss; flow not drawable. SENS: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only RNA
0
None
Shared
0
No disclosed counterparties: RNA.
Only SENS
3
—
BSI
unlisted
supplier
—
NPG
unlisted
supplier
—
Ascensia Diabetes Care Holdings AG ("Ascensia")
unlisted
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
RNA
Atrium Therapeutics, Inc.
Change
8.28
▲
+0.21%
· post 8.36
Mkt cap
$141.5M
Revenue
$3M
Q2 FY26
Revenue
—
SENS
Senseonics Holdings, Inc.
Change
9.50
▼
−2.56%
· post 9.50
Closed
Oct 30 '26
Mkt cap
$502.8M
Revenue
$14M
Q2 FY26
Revenue
$35M
FY25
vs
Compare
Closed
Oct 30 '26
RNA
Atrium Therapeutics, Inc.
vs
SENS
Senseonics Holdings, Inc.
8.28
▲
+0.21%
post 8.36
Price
9.50
▼
−2.56%
post 9.50
$141.5M
Mkt cap
$502.8M
Q2 FY26
$3M
Revenue
$14M
Q2 FY26
—
Revenue
$35M
FY25
Change
Change
RNA
8.28
▲
+0.21%
vs
SENS
9.50
▼
−2.56%
Closed
Oct 30 '26